For comparison, GHK-Cu differs from NAD+ therapy, which targets cellular energy pathways rather than tissue remodeling
The findings appeared on July 22, 2025 in BMJ Open Diabetes Research & Care Given the severe societal, familial, and economic burden of diabetes-related dementia, these findings raise important considerations about the role of GLP-1 [receptor agonists] as first-line therapies in [type 2 diabetes] management, the authors said
Pharmaceuticals 14(6):569
Regulatory & Serious Safety Alerts The U.S
Using GLP-1 to increase insulin secretion while slowing down how fast your stomach empties food works in the following ways: Slowed digestion Reduced appetite Stabilized blood sugar & energy At Saving Face, every GLP-1 treatment is supported by expert oversight, baseline lab testing, and personalized nutrition guidance
Mechanism ColonBroom's GLP-1 positioning is backed by real fiber science: fermentable fiber increases short-chain fatty acids, which activate receptors on gut L-cells that release GLP-1 and PYY, both of which increase fullness